AbCellera Announces Expanded Research Collaboration with Teva
(Thomson Reuters ONE) -
Collaboration extends initial partnership and aims to generate lead antibody
candidates against membrane targets using AbCellera's antibody discovery
platform
VANCOUVER, British Columbia, June 13, 2017 (GLOBE NEWSWIRE) -- AbCellera
Biologics, Inc. announced today a new therapeutic antibody discovery
collaboration with Teva Pharmaceutical Industries, Ltd. Under the agreement,
which builds on a successful first partnership completed in 2016, AbCellera will
apply its proprietary monoclonal antibody (mAb) screening platform for the
discovery of antibodies that modulate the function of an undisclosed membrane
protein target elected by Teva.
Carl Hansen, founding CEO of AbCellera, commented: "We are excited to expand our
relationship with the innovative team at Teva. This follow-on project marks an
important step in establishing AbCellera's platform as an enabling technology
for difficult target classes that have proven intractable by conventional
antibody discovery methods."
"We are pleased to extend our work with AbCellera utilizing this company's novel
biologics technology," said Steffen Nock, SVP & Global Head of Biologics at
Teva. "This agreement will be complementary to our existing antibody discovery
process with the potential to strengthen Teva's capabilities in novel biologics
discovery."
Under the terms of the agreement, AbCellera will receive an upfront payment and
research support, as well as milestone and royalty payments based on Teva's
development and commercialization of antibodies generated under this
collaboration. Further terms of the agreement are not disclosed.
About AbCellera Biologics, Inc.
AbCellera is a privately held company that develops next-generation monoclonal
antibody therapies and provides enabling technologies to biotechnology and
pharmaceutical partners. AbCellera's lead technology is a proprietary single-
cell antibody discovery and immune profiling platform that allows for high-
throughput screening of natural immune repertoires to rapidly identify lead
therapeutic antibody candidates from any species, including humans.
Contact
Kevin Heyries, PhD
Telephone: 604.827.4151
Email: media(at)abcellera.com
Web: www.abcellera.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AbCellera via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Nexus Gold Commences Drilling at Bouboulou Gold Concession, Burkina Faso, West AfricaDatum: 13.06.2017 - 15:00 Uhr
Sprache: Deutsch
News-ID 547689
Anzahl Zeichen: 2947
contact information:
Town:
Vancouver
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 196 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AbCellera Announces Expanded Research Collaboration with Teva"
steht unter der journalistisch-redaktionellen Verantwortung von
AbCellera (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
